• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Owning Research Integrity: Make It Everyone’s Obligation

Owning Research Integrity: Make It Everyone’s Obligation

reduce time
October 7, 2019
Colin Stoecker

Defending against research misconduct is the responsibility of everyone involved in a trial, from the principal investigator down to the lowest lab technician.

Red flags can appear in any aspect of a trial, ranging from missing or altered data, significant omissions in published reports, investigators’ failure to disclose intellectual property interests or industry relationships, and generally results that seem too good to be true or apparently “perfect” protocol compliance, Donna Kessler, Duke University research misconduct review officer, reminded attendees at the Society of Clinical Research Associates annual conference last week.

Another warning sign, she said, is an investigator’s refusal to share raw data or detailed methods. And serious or recurring episodes of non-compliance also bear a closer look.

Kessler also noted that there are practices that aren’t misconduct themselves but can create the environment for misconduct to flourish. For instance, unprofessional behavior — bullying, harassment and discrimination in the lab — can create a barrier to staff reports of misconduct.

Trial staff actually identify more cases of misconduct than trial monitors do, said attorney Debra Parrish.

For example, a financial audit of a Stanford University trial turned up evidence of falsified data and led to a three-year disqualification for the principal investigator. In another instance at the University of Vermont, a lab technician suspected the investigator had falsified data. The tech’s report eventually led to the investigator’s admission that he had committed research misconduct in multiple cases.

It’s important to create an environment in which reporters feel protected, Kessler said. Research institutions should normalize the process with such policies as anonymous reporting options, ombudsman services and prohibition of retaliation. They also can provide their investigators with role models, peer counseling and mentoring of professional behavior.

“Cultivate good citizens, managers and mentors, not just good researchers,” she said.

Although research integrity is a universal obligation, the ultimate responsibility is on the principal investigator’s shoulders. “Some places take the position that the PI is the captain of the ship,” said Parrish. “If the ship goes down, the captain goes down.”

Research scientists need to practice more transparency, Kessler said, explaining their methods, outlining results obtained and sharing source data. Investigators also need to provide better oversight, supervision and mentoring of the trial staff. Frequent discussions about ethics and integrity in research can help keep the ideas fresh in their minds, she said.

PIs should set expectations for data management and conduct routine reviews, Kessler said, recommending giving staff tools to improve record-keeping and reporting, such as auditable systems and electronic notebooks.

Research is not flawless, she said, and researchers need to acknowledge that errors and experimental failure are a normal part of science. Deal with problems transparently and ethically.

“Make the error occur the right way,” she said, and learn from it.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing